Department of Biological Sciences and Center for Colon Cancer Research, University of South Carolina, Columbia, SC 29208, USA.
Oncogene. 2012 Mar 22;31(12):1592-8. doi: 10.1038/onc.2011.349. Epub 2011 Aug 8.
Elevated expression of the prostaglandin synthase cyclooxygenase-2 (COX-2) is commonly observed in many chronic inflammatory diseases and cancer. However, the mechanisms allowing for pathogenic COX-2 overexpression are largely unknown. The gene for COX-2 (PTGS2) carries a common single-nucleotide polymorphism (SNP) at position 8473 (T8473C), in exon 10 that is associated with diseases in which COX-2 overexpression is a contributing factor. We demonstrate that the T8473C SNP resides within a region that targets COX-2 mRNA for degradation through microRNA-mediated regulation. miR-542-3p was identified to bind transcripts derived from the 8473T allele and promote mRNA decay. By contrast, the presence of the variant 8473C allele interfered with miR-542-3p binding, allowing for mRNA stabilization, and this effect was rescued using a mutated miR-542-3p at the respective 8473 site. Colon cancer cells and tissue displayed COX-2 mRNA levels that were dependent on T8473C allele dosage, and allele-specific expression of COX-2 was observed to be a contributing factor promoting COX-2 overexpression. These findings provide a novel molecular explanation underlying disease susceptibility associated with COX-2 T8473C SNP, and identify it as a potential marker for identifying cancer patients best served through selective COX-2 inhibition.
前列腺素合酶环氧化酶-2(COX-2)的表达升高通常在许多慢性炎症性疾病和癌症中观察到。然而,导致致病 COX-2 过表达的机制在很大程度上尚不清楚。COX-2(PTGS2)基因在 10 号外显子中携带一个常见的单核苷酸多态性(SNP),位置为 8473(T8473C),与 COX-2 过表达是致病因素的疾病有关。我们证明,T8473C SNP 位于一个通过 microRNA 介导的调节靶向 COX-2 mRNA 降解的区域。miR-542-3p 被鉴定为与源自 8473T 等位基因的转录本结合,并促进 mRNA 降解。相比之下,变异型 8473C 等位基因的存在干扰了 miR-542-3p 的结合,允许 mRNA 稳定,并且通过在相应的 8473 位点使用突变的 miR-542-3p 可以挽救这种效应。结肠癌细胞和组织显示出依赖于 T8473C 等位基因剂量的 COX-2 mRNA 水平,并且观察到 COX-2 的等位基因特异性表达是促进 COX-2 过表达的一个致病因素。这些发现为 COX-2 T8473C SNP 相关疾病易感性提供了一个新的分子解释,并将其确定为一种潜在的标记,用于识别最适合通过选择性 COX-2 抑制治疗的癌症患者。